BACKGROUND Coronary heart disease(CHD)and heart failure(HF)are the major causes of morbidity and mortality worldwide.Early and accurate diagnoses of CHD and HF are essential for optimal management and prognosis.Howeve...BACKGROUND Coronary heart disease(CHD)and heart failure(HF)are the major causes of morbidity and mortality worldwide.Early and accurate diagnoses of CHD and HF are essential for optimal management and prognosis.However,conventional diagnostic methods such as electrocardiography,echocardiography,and cardiac biomarkers have certain limitations,such as low sensitivity,specificity,availability,and cost-effectiveness.Therefore,there is a need for simple,noninvasive,and reliable biomarkers to diagnose CHD and HF.AIM To investigate serum cystatin C(Cys-C),monocyte/high-density lipoprotein cholesterol ratio(MHR),and uric acid(UA)diagnostic values for CHD and HF.METHODS We enrolled 80 patients with suspected CHD or HF who were admitted to our hospital between July 2022 and July 2023.The patients were divided into CHD(n=20),HF(n=20),CHD+HF(n=20),and control groups(n=20).The serum levels of Cys-C,MHR,and UA were measured using immunonephelometry and an enzymatic method,respectively,and the diagnostic values for CHD and HF were evaluated using receiver operating characteristic(ROC)curve analysis.RESULTS Serum levels of Cys-C,MHR,and UA were significantly higher in the CHD,HF,and CHD+HF groups than those in the control group.The serum levels of Cys-C,MHR,and UA were significantly higher in the CHD+HF group than those in the CHD or HF group.The ROC curve analysis showed that serum Cys-C,MHR,and UA had good diagnostic performance for CHD and HF,with areas under the curve ranging from 0.78 to 0.93.The optimal cutoff values of serum Cys-C,MHR,and UA for diagnosing CHD,HF,and CHD+HF were 1.2 mg/L,0.9×10^(9),and 389μmol/L;1.4 mg/L,1.0×10^(9),and 449μmol/L;and 1.6 mg/L,1.1×10^(9),and 508μmol/L,respectively.CONCLUSION Serum Cys-C,MHR,and UA are useful biomarkers for diagnosing CHD and HF,and CHD+HF.These can provide information for decision-making and risk stratification in patients with CHD and HF.展开更多
Objective: To analyze the serum uric acid results of patients with hypouricemia hospitalized in the Affiliated Hospital of Hebei University, thereby providing new insights for the prevention and treatment of hypourice...Objective: To analyze the serum uric acid results of patients with hypouricemia hospitalized in the Affiliated Hospital of Hebei University, thereby providing new insights for the prevention and treatment of hypouricemia. Method: This study employed a retrospective case analysis, dividing patients into two groups: 16 cases with uric acid levels less than 50 μmol/L (group Level 1), and 240 cases with uric acid levels between 50 μmol/L and 119 μmol/L (group Level 2). Basic data such as age, gender, department, and clinical diagnosis were collected for each patient. Renal indices, including creatinine, urea, β2-microglobulin, and cystatin C, were analyzed and compared. Results: The highest percentage of patients with uremia was found in Level 1, with a rate of 31.25%. In Level 2, the highest percentage of patients had malignant tumors, with a rate of 15.41%. Tumor sites included the liver, lungs, endometrium, ovaries, breasts, stomach, pancreas, colon, hypopharynx, and others. The second highest percentage was 13.75% for patients with lung diseases, followed by 10% for patients with cranio-cerebral diseases. Other prevalent conditions included renal diseases, hematological diseases, multiple injuries, orthopedic diseases, rheumatological-immunological diseases, and cardiac diseases. There were significant differences between the two uric acid level groups in terms of prevalent diseases (P < 0.05). Additionally, gender differences were significant between the two groups (P < 0.05). However, for renal disease indicators, no significant differences were found between the two levels (P > 0.05). Conclusion: The types of diseases presented by patients were related to different low uric acid levels. Most patients‘ renal function indices were within normal reference ranges at different low uric acid levels. The prevalence of different low uric acid levels was related to gender.展开更多
目的探索脊柱退变住院患者血清尿酸/高密度脂蛋白比值与骨密度的相关性。方法共纳入803例脊柱退变的受试者,评估临床因素及实验室检查结果,测量骨密度,按照骨密度结果分为骨质疏松症组及非骨质疏松症组。采用多元Logistic回归分析血清尿...目的探索脊柱退变住院患者血清尿酸/高密度脂蛋白比值与骨密度的相关性。方法共纳入803例脊柱退变的受试者,评估临床因素及实验室检查结果,测量骨密度,按照骨密度结果分为骨质疏松症组及非骨质疏松症组。采用多元Logistic回归分析血清尿酸/高密度脂蛋白比值(uric acid to high-density lipoprotein cholesterol ratio,UHR)与骨质疏松症的相关性。结果与非骨质疏松症组相比,骨质疏松症组的UHR更低(244.93±.102.51 vs 199.97±.91.96,P<0.001),多元Logistics回归分析提示,在校正了骨质疏松症的传统危险因素后,UHR最高的四分位患者发生骨质疏松症的可能性是UHR最低的四分位患者的0.402倍(P=0.018)。骨质疏松症的患病率在UHR四分位呈下降的趋势,骨密度在UHR四分位呈升高的趋势。UHR在骨量正常、骨量减少及骨质疏松症3组呈下降的趋势。结论低UHR是昆山地区脊柱退变住院患者发生骨质疏松症的危险因素。对于UHR较低的脊柱退变患者,应注意筛查骨质疏松症。展开更多
目的通过分析血清胱抑素C(Cys-C)、β2微球蛋白(β2-MG)、尿酸(UA)等联合项目与糖尿病肾病(DN)的相关性,从而找出准确诊断DN的相关因素。方法选取259名糖尿病(DM)患者,收集Cys-C、β2-MG、UA等相关项目指标,运用相应的统计学方法分析相...目的通过分析血清胱抑素C(Cys-C)、β2微球蛋白(β2-MG)、尿酸(UA)等联合项目与糖尿病肾病(DN)的相关性,从而找出准确诊断DN的相关因素。方法选取259名糖尿病(DM)患者,收集Cys-C、β2-MG、UA等相关项目指标,运用相应的统计学方法分析相关项目与尿白蛋白/肌酐比值(UACR)的关系。结果UACR≥30 mg/g作为DN的诊断临界点时,显示Cys-C、β2-MG、UA、收缩压(SBP)、餐后2 h血糖(2 h PG)、病程等6个项目是UACR的独立危险因素,当某一DM患者Cys-C≥1.435 mg/L、β2-MG≥2.055 mg/L、UA≥320μmol/L、SBP≥145 mmHg、2 h PG≥8.5 mmol/L、病程≥4.5年时,患者发展成早期DN的风险较大,相对应的临界值患病概率为81.5%。结论联合检测Cys-C、β2-MG、UA、SBP、2 h PG、病程等6个项目可以较好预测DN的发生。展开更多
文摘BACKGROUND Coronary heart disease(CHD)and heart failure(HF)are the major causes of morbidity and mortality worldwide.Early and accurate diagnoses of CHD and HF are essential for optimal management and prognosis.However,conventional diagnostic methods such as electrocardiography,echocardiography,and cardiac biomarkers have certain limitations,such as low sensitivity,specificity,availability,and cost-effectiveness.Therefore,there is a need for simple,noninvasive,and reliable biomarkers to diagnose CHD and HF.AIM To investigate serum cystatin C(Cys-C),monocyte/high-density lipoprotein cholesterol ratio(MHR),and uric acid(UA)diagnostic values for CHD and HF.METHODS We enrolled 80 patients with suspected CHD or HF who were admitted to our hospital between July 2022 and July 2023.The patients were divided into CHD(n=20),HF(n=20),CHD+HF(n=20),and control groups(n=20).The serum levels of Cys-C,MHR,and UA were measured using immunonephelometry and an enzymatic method,respectively,and the diagnostic values for CHD and HF were evaluated using receiver operating characteristic(ROC)curve analysis.RESULTS Serum levels of Cys-C,MHR,and UA were significantly higher in the CHD,HF,and CHD+HF groups than those in the control group.The serum levels of Cys-C,MHR,and UA were significantly higher in the CHD+HF group than those in the CHD or HF group.The ROC curve analysis showed that serum Cys-C,MHR,and UA had good diagnostic performance for CHD and HF,with areas under the curve ranging from 0.78 to 0.93.The optimal cutoff values of serum Cys-C,MHR,and UA for diagnosing CHD,HF,and CHD+HF were 1.2 mg/L,0.9×10^(9),and 389μmol/L;1.4 mg/L,1.0×10^(9),and 449μmol/L;and 1.6 mg/L,1.1×10^(9),and 508μmol/L,respectively.CONCLUSION Serum Cys-C,MHR,and UA are useful biomarkers for diagnosing CHD and HF,and CHD+HF.These can provide information for decision-making and risk stratification in patients with CHD and HF.
文摘Objective: To analyze the serum uric acid results of patients with hypouricemia hospitalized in the Affiliated Hospital of Hebei University, thereby providing new insights for the prevention and treatment of hypouricemia. Method: This study employed a retrospective case analysis, dividing patients into two groups: 16 cases with uric acid levels less than 50 μmol/L (group Level 1), and 240 cases with uric acid levels between 50 μmol/L and 119 μmol/L (group Level 2). Basic data such as age, gender, department, and clinical diagnosis were collected for each patient. Renal indices, including creatinine, urea, β2-microglobulin, and cystatin C, were analyzed and compared. Results: The highest percentage of patients with uremia was found in Level 1, with a rate of 31.25%. In Level 2, the highest percentage of patients had malignant tumors, with a rate of 15.41%. Tumor sites included the liver, lungs, endometrium, ovaries, breasts, stomach, pancreas, colon, hypopharynx, and others. The second highest percentage was 13.75% for patients with lung diseases, followed by 10% for patients with cranio-cerebral diseases. Other prevalent conditions included renal diseases, hematological diseases, multiple injuries, orthopedic diseases, rheumatological-immunological diseases, and cardiac diseases. There were significant differences between the two uric acid level groups in terms of prevalent diseases (P < 0.05). Additionally, gender differences were significant between the two groups (P < 0.05). However, for renal disease indicators, no significant differences were found between the two levels (P > 0.05). Conclusion: The types of diseases presented by patients were related to different low uric acid levels. Most patients‘ renal function indices were within normal reference ranges at different low uric acid levels. The prevalence of different low uric acid levels was related to gender.
文摘目的探索脊柱退变住院患者血清尿酸/高密度脂蛋白比值与骨密度的相关性。方法共纳入803例脊柱退变的受试者,评估临床因素及实验室检查结果,测量骨密度,按照骨密度结果分为骨质疏松症组及非骨质疏松症组。采用多元Logistic回归分析血清尿酸/高密度脂蛋白比值(uric acid to high-density lipoprotein cholesterol ratio,UHR)与骨质疏松症的相关性。结果与非骨质疏松症组相比,骨质疏松症组的UHR更低(244.93±.102.51 vs 199.97±.91.96,P<0.001),多元Logistics回归分析提示,在校正了骨质疏松症的传统危险因素后,UHR最高的四分位患者发生骨质疏松症的可能性是UHR最低的四分位患者的0.402倍(P=0.018)。骨质疏松症的患病率在UHR四分位呈下降的趋势,骨密度在UHR四分位呈升高的趋势。UHR在骨量正常、骨量减少及骨质疏松症3组呈下降的趋势。结论低UHR是昆山地区脊柱退变住院患者发生骨质疏松症的危险因素。对于UHR较低的脊柱退变患者,应注意筛查骨质疏松症。
文摘目的通过分析血清胱抑素C(Cys-C)、β2微球蛋白(β2-MG)、尿酸(UA)等联合项目与糖尿病肾病(DN)的相关性,从而找出准确诊断DN的相关因素。方法选取259名糖尿病(DM)患者,收集Cys-C、β2-MG、UA等相关项目指标,运用相应的统计学方法分析相关项目与尿白蛋白/肌酐比值(UACR)的关系。结果UACR≥30 mg/g作为DN的诊断临界点时,显示Cys-C、β2-MG、UA、收缩压(SBP)、餐后2 h血糖(2 h PG)、病程等6个项目是UACR的独立危险因素,当某一DM患者Cys-C≥1.435 mg/L、β2-MG≥2.055 mg/L、UA≥320μmol/L、SBP≥145 mmHg、2 h PG≥8.5 mmol/L、病程≥4.5年时,患者发展成早期DN的风险较大,相对应的临界值患病概率为81.5%。结论联合检测Cys-C、β2-MG、UA、SBP、2 h PG、病程等6个项目可以较好预测DN的发生。
